Cabozantinib is used in two forms. A capsule form is used since 2012 to treat medullary thyroid cancer and a tablet form is used since 2016 as a second line treatment for renal cell carcinoma.. Reference standards of Cabozantinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below
stdClass Object ( [pname] => Cabozantinib L-Malate Salt (BSC) [catalogue_number] => PA BSC 06230258 [category_ids] => ,169, [chemical_name] => [weight] => 635.6 [form] => C32H30FN3O10 [cas] => 1140909-48-3 [pslug] => 1140909-48-3-cabozantinib-l-malate-salt-bsc-pabsc06230258 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA BSC 06230258
CAS :
Molecular Formula : C32H30FN3O10
Molecular Weight : 635.6
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....